These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 29897025)
1. COMPARATIVE EFFECTIVENESS AND SAFETY BETWEEN AMPHOTERICIN B LIPID-FORMULATIONS: A SYSTEMATIC REVIEW. Grazziotin LR; Moreira LB; Ferreira MAP Int J Technol Assess Health Care; 2018 Jan; 34(3):343-351. PubMed ID: 29897025 [TBL] [Abstract][Full Text] [Related]
2. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Saliba F; Dupont B Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488 [TBL] [Abstract][Full Text] [Related]
3. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Barrett JP; Vardulaki KA; Conlon C; Cooke J; Daza-Ramirez P; Evans EG; Hawkey PM; Herbrecht R; Marks DI; Moraleda JM; Park GR; Senn SJ; Viscoli C; Clin Ther; 2003 May; 25(5):1295-320. PubMed ID: 12867214 [TBL] [Abstract][Full Text] [Related]
4. Amphotericin B formulations: a comparative review of efficacy and toxicity. Hamill RJ Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001 [TBL] [Abstract][Full Text] [Related]
5. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Kuti JL; Kotapati S; Williams P; Capitano B; Nightingale CH; Nicolau DP Pharmacoeconomics; 2004; 22(5):301-10. PubMed ID: 15061680 [TBL] [Abstract][Full Text] [Related]
6. A prospective and retrospective analysis of the nephrotoxicity and efficacy of lipid-based amphotericin B formulations. Cannon JP; Garey KW; Danziger LH Pharmacotherapy; 2001 Sep; 21(9):1107-14. PubMed ID: 11560200 [TBL] [Abstract][Full Text] [Related]
7. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability. Tiphine M; Letscher-Bru V; Herbrecht R Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998 [TBL] [Abstract][Full Text] [Related]
8. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: a retrospective, nonrandomized autopsy study. Chamilos G; Luna M; Lewis RE; Chemaly R; Raad II; Kontoyiannis DP Clin Ther; 2007 Sep; 29(9):1980-6. PubMed ID: 18035197 [TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex. Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005 [TBL] [Abstract][Full Text] [Related]
10. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies--a randomized, controlled trial. Subirà M; Martino R; Gómez L; Martí JM; Estany C; Sierra J Eur J Haematol; 2004 May; 72(5):342-7. PubMed ID: 15059069 [TBL] [Abstract][Full Text] [Related]
11. Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States. Yang H; Chaudhari P; Zhou ZY; Wu EQ; Patel C; Horn DL Appl Health Econ Health Policy; 2014 Feb; 12(1):85-93. PubMed ID: 24385260 [TBL] [Abstract][Full Text] [Related]
12. The evaluation of frequency of nephrotoxicity caused by liposomal amphotericin B. Kato H; Hagihara M; Yamagishi Y; Shibata Y; Kato Y; Furui T; Watanabe H; Asai N; Koizumi Y; Mikamo H J Infect Chemother; 2018 Sep; 24(9):725-728. PubMed ID: 29773439 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and cost-effectiveness of Amphotericin B Lipid Complex (ABLC): a review of the literature. Martino R Curr Med Res Opin; 2004 Apr; 20(4):485-504. PubMed ID: 15119986 [TBL] [Abstract][Full Text] [Related]
14. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study. Falci DR; da Rosa FB; Pasqualotto AC Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436 [TBL] [Abstract][Full Text] [Related]
15. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Prentice HG; Hann IM; Herbrecht R; Aoun M; Kvaloy S; Catovsky D; Pinkerton CR; Schey SA; Jacobs F; Oakhill A; Stevens RF; Darbyshire PJ; Gibson BE Br J Haematol; 1997 Sep; 98(3):711-8. PubMed ID: 9332329 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Amphotericin B Lipid Formulations for Treatment of Severe Coccidioidomycosis. Sidhu R; Lash DB; Heidari A; Natarajan P; Johnson RH Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686150 [TBL] [Abstract][Full Text] [Related]
17. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Brogden RN; Goa KL; Coukell AJ Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313 [TBL] [Abstract][Full Text] [Related]
18. Renal effects of amphotericin B lipid complex. Luke RG; Boyle JA Am J Kidney Dis; 1998 May; 31(5):780-5. PubMed ID: 9590187 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness, Tolerability, and Safety of Different Amphotericin B Formulations in Invasive Fungal Infections: A Multicenter, Retrospective, Observational Study. Cavassin FB; Magri MMC; Vidal JE; de Moraes Costa Carlesse FA; Falci DR; Baú-Carneiro JL; Breda GL; de Araújo Motta F; de Miranda Godoy CS; de Bastos Ascenço Soares R; De Oliveira CS; Mendes AVA; Morales HP; Montes PS; Taborda M; Rego CM; Félix MA; Katopodis PP; da Silva do Ó JR; Abrão MPL; Pereira TTT; Queiroz-Telles F Clin Ther; 2024 Apr; 46(4):322-337. PubMed ID: 38403508 [TBL] [Abstract][Full Text] [Related]
20. Amphotericin B lipid complex. Rapp RP; Gubbins PO; Evans ME Ann Pharmacother; 1997 Oct; 31(10):1174-86. PubMed ID: 9337444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]